Community-based intermittent mass testing and treatment for malaria in an area of high transmission intensity, western Kenya: study design and methodology for a cluster randomized controlled trial

This manuscript describes the study design and methodology of a cluster-randomized controlled trial to evaluate a mass testing and treatment approach for malaria transmission reduction in an area of high malaria transmission in western Kenya.

Author: , , , , , , , , , , , , , , , , , ,
Publication date: June 2017
Source: Malaria Journal

Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial

RTS, S/AS01 was well tolerated when given to children with WHO clinical stage 1 or 2 HIV disease along with high antiretroviral and co-trimoxazole use. Children with HIV disease could be included in future RTS,S/AS01 vaccination programmes.

Author: , , , , , , , , , , , , , , , , , , , , , , , , , ,
Publication date: October 2016
Source: The Lancet Infectious Diseases

Preventive malaria treatment for contacts of patients with Ebola virus disease in the context of the west Africa 2014–15 Ebola virus disease response: an economic analysis

This study aimed to assess the economic feasibility of administering preventive malaria treatment to all contacts of patients with Ebola virus disease, to prevent the onset of febrile malaria and subsequent admission to Ebola treatment units. Administration of ACTs was cost saving for contacts of all ages.

Author: , , , ,
Publication date: April 2016
Source: The Lancet Infectious Diseases

Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites

This journal article reports the safety and vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria transmission

Publication date: July 2014
Source: PLOS Medicine